Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03365635 · ClinicalTrials.gov registry record · Phase 4
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
A Phase 4 study of Hepatitis C and Hemodialysis, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT03365635 is a Phase 4 study of Hepatitis C and Hemodialysis that has completed, run by University of Pennsylvania. The registered enrollment target is 6 participants, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03365635, a Phase 4 study of Hepatitis C and Hemodialysis, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study to define strategies for Nephrologists to directly supervise and apply direct acting antivirals to cure hepatitis C in hemodialysis patients. Strategies will include identification of candidate patients, application for insurance approval, specifics of direct acting antiviral therapy (Zepatier with or without ribavirin) and laboratory monitoring during and after therapy.
Conditions Studied
Interventions
- DRUG Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier]
Study Locations (1)
Pennsylvania
- Penn Presbyterian Medical Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-09-22 |
| Est. Completion | 2020-09-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03365635
The ClinicalTrials.gov registry entry for NCT03365635 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (100% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Hepatitis C appearing as the primary indexed condition, and to 1 intervention - of which Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier] is the first listed.
NCT03365635 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03365635 about?
NCT03365635 is a clinical study titled "Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C". This is a study to define strategies for Nephrologists to directly supervise and apply direct acting antivirals to cure hepatitis C in hemodialysis patients. Strategies will include identification of candidate patients, application for insurance approval, specifics of direct acting antiviral therapy...
What is the current status of trial NCT03365635?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2019-09-22. Estimated completion is 2020-09-01.
What conditions does trial NCT03365635 study?
This clinical trial studies the following conditions: Hepatitis C, Hemodialysis, Nosocomial Infection.
What interventions are being tested in trial NCT03365635?
The interventions under investigation include: Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier] (DRUG).
Who is sponsoring clinical trial NCT03365635?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03365635 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients
ACTIVE NOT RECRUITING · Phase 4
-
Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
COMPLETED · Phase 4
-
Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection
COMPLETED · Phase 4
-
Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC
COMPLETED · Phase 4
-
The Kentucky Viral Hepatitis Treatment Study
COMPLETED · Phase 4
-
Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.